UPDATE: UBS Upgrades LPL Investment (LPLA) to Neutral
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 10, 2016 9:51 AM EST)
UBS upgraded LPL Investment (NASDAQ: LPLA) from Sell to Neutral with a price target of $35.00 (from $24.00).
Analyst Alex Kramm said, "The results of the US presidential election signal a regime change in Washington that could result in the reversal of several regulatory initiatives. Among them is the DOL's fiduciary standard rule, which had already been challenged by members of the president-elect's party, only to be vetoed by the outgoing president (InvestmentNews, 11/9/2016: "Trump victory puts DOL fiduciary rule in limbo"). Given the possibility that the rule could be put aside by the new administration, our negative thesis for LPLA has lost some of its footing. Previously-imminent headwinds from compliance spending and reduced commissions may be alleviated, and sentiment has already improved significantly in response to headlines that the rule could be repealed. We believe yesterday’s move in the shares fairly captures the potential upside, leading to our new Neutral rating."
Shares of LPL Investment closed at $35.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades Juniper Networks (JNPR) to Outperform
- Wedbush Raises Price Target on Francesca's (FRAN) Following 3Q Report
- UPDATE: Oppenheimer Upgrades Envision Healthcare (EVHC) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!